Last 12 months
Inside the activity.
0 purchase rows · 28 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 7 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 13 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2021 Filed Sep 2, 2021 21:26 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 1,285 | $29.43 | $37,817.55 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,759,840 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:48 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 31,001 | $29.30 | $908,329.30 |
DisclosureSEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,761,125 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:48 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 4,285 | $29.30 | $125,550.50 |
DisclosureSEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,152 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:47 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 31,001 | $29.30 | $908,329.30 |
DisclosureSEC source: 0001209191-21-054093 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,761,125 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:48 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 13,357 | $29.09 | $388,555.13 |
DisclosureSEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,792,126 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:48 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,846 | $29.09 | $53,700.14 |
DisclosureSEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,437 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:47 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 13,357 | $29.09 | $388,555.13 |
DisclosureSEC source: 0001209191-21-054093 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,792,126 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 25, 2021 23:41 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,713 | $29.09 | $49,831.17 |
DisclosureSEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,805,483 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 25, 2021 23:41 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 237 | $29.09 | $6,894.33 |
DisclosureSEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,283 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2021 Filed Aug 25, 2021 23:42 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 1,713 | $29.09 | $49,831.17 |
DisclosureSEC source: 0001209191-21-053380 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,805,483 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 23:41 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 50,882 | $29.48 | $1,500,001.36 |
DisclosureSEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,807,196 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 23:41 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 7,025 | $29.48 | $207,097.00 |
DisclosureSEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,520 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 23:42 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 50,822 | $29.48 | $1,498,232.56 |
DisclosureSEC source: 0001209191-21-053380 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,807,196 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:06 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 28,118 | $29.00 | $815,422.00 |
DisclosureSEC source: 0000899243-21-034027 · doc4.xml · nonDerivative · entry 1 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,524 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 23:41 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 53,359 | $29.11 | $1,553,280.49 |
DisclosureSEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,858,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 23:41 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 7,376 | $29.11 | $214,715.36 |
DisclosureSEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,545 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 23:42 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 53,359 | $29.11 | $1,553,280.49 |
DisclosureSEC source: 0001209191-21-053380 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,858,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 23:14 UTC Amendment |
Zawel LeighSee Remarks
|
SaleCommon Stock | 28,118 | $29.00 | $815,422.00 |
DisclosureSEC source: 0000899243-21-034311 · doc4a.xml · nonDerivative · entry 1 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,524 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC |
Michaelson JenniferSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,978 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC |
Michaelson JenniferSee Remarks
|
SaleCommon Stock | 1,137 | $28.07 | $31,915.59 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC |
Michaelson JenniferSee Remarks
|
SaleCommon Stock | 2,863 | $27.50 | $78,732.50 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,048 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 24, 2021 20:06 UTC |
Michaelson JenniferSee Remarks
|
Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-21-034025 · doc4.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment |
Michaelson JenniferSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,978 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment |
Michaelson JenniferSee Remarks
|
SaleCommon Stock | 1,137 | $28.07 | $31,915.59 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment |
Michaelson JenniferSee Remarks
|
SaleCommon Stock | 2,863 | $27.50 | $78,732.50 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,048 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 26, 2021 23:15 UTC Amendment |
Michaelson JenniferSee Remarks
|
Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0000899243-21-034312 · doc4a.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 20:54 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 2,510 | $29.05 | $72,915.50 |
DisclosureSEC source: 0001209191-21-051147 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,911,377 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 20:54 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 347 | $29.05 | $10,080.35 |
DisclosureSEC source: 0001209191-21-051147 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,921 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 20:55 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 2,510 | $29.05 | $72,915.50 |
DisclosureSEC source: 0001209191-21-051148 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911,377 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:15 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 1,817 | $28.49 | $51,766.33 |
DisclosureSEC source: 0000899243-21-032515 · doc4.xml · nonDerivative · entry 5 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,642 F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:15 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 3,191 | $27.34 | $87,241.94 |
DisclosureSEC source: 0000899243-21-032515 · doc4.xml · nonDerivative · entry 4 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,459 F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:15 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 1,906 | $26.50 | $50,509.00 |
DisclosureSEC source: 0000899243-21-032515 · doc4.xml · nonDerivative · entry 3 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,650 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 19:11 UTC |
Baeuerle PatrickSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-034306 · doc4.xml · derivative · entry 4 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,114 Underlying: Common Stock · 11,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 19:11 UTC |
Baeuerle PatrickSee Remarks
|
SaleCommon Stock | 11,000 | $27.00 | $297,000.00 |
DisclosureSEC source: 0000899243-21-034306 · doc4.xml · nonDerivative · entry 2 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 19:11 UTC |
Baeuerle PatrickSee Remarks
|
Exercise / conversionCommon Stock | 11,000 | $4.30 | $47,300.00 |
DisclosureSEC source: 0000899243-21-034306 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 23:20 UTC Amendment |
Zawel LeighSee Remarks
|
SaleCommon Stock | 1,817 | $28.49 | $51,766.33 |
DisclosureSEC source: 0000899243-21-034314 · doc4a.xml · nonDerivative · entry 5 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,642 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F6 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 23:20 UTC Amendment |
Zawel LeighSee Remarks
|
SaleCommon Stock | 3,191 | $27.34 | $87,241.94 |
DisclosureSEC source: 0000899243-21-034314 · doc4a.xml · nonDerivative · entry 4 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,459 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 23:20 UTC Amendment |
Zawel LeighSee Remarks
|
SaleCommon Stock | 1,906 | $26.50 | $50,509.00 |
DisclosureSEC source: 0000899243-21-034314 · doc4a.xml · nonDerivative · entry 3 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,650 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 20:15 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 1,700 | $27.11 | $46,087.00 |
DisclosureSEC source: 0000899243-21-032515 · doc4.xml · nonDerivative · entry 2 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,556 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 20:15 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 19,504 | $26.52 | $517,246.08 |
DisclosureSEC source: 0000899243-21-032515 · doc4.xml · nonDerivative · entry 1 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,256 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 26, 2021 23:20 UTC Amendment |
Zawel LeighSee Remarks
|
SaleCommon Stock | 1,700 | $27.11 | $46,087.00 |
DisclosureSEC source: 0000899243-21-034314 · doc4a.xml · nonDerivative · entry 2 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,556 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 26, 2021 23:20 UTC Amendment |
Zawel LeighSee Remarks
|
SaleCommon Stock | 19,504 | $26.52 | $517,246.08 |
DisclosureSEC source: 0000899243-21-034314 · doc4a.xml · nonDerivative · entry 1 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,256 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionSeries C Convertible Preferred Stock · Derivative | 649,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 16 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 649,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 2,276,692 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 15 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,276,692 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 3,551,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 14 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,551,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionSeries Seed Convertible Preferred Stock · Derivative | 1,136,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 13 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,136,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
PurchaseCommon Stock | 300,000 | $21.00 | $6,300,000.00 |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 7,913,887 F6 · kind: On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionCommon Stock | 649,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 7,613,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionCommon Stock | 2,276,692 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,964,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:51 UTC |
GADICKE ANSBERTDirector · 10% owner
|
ConversionCommon Stock | 3,551,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002076 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,688,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.